Pathomorphological and immunohistochemical characteristics of vascularisation in benign and malignant meningiomas of the brain


  • Wanda Voteva Department of Pathological Anatomy and Forensic Medicine, Zaporozhye State Medical University, Zaporozhye, Ukraine



meningioma, angiogenesis, vascular endothelial growth factor, vascular endothelial growth factor receptor-1


Aim. To determine the expression level of angiogenesis markers VEGF and VEGFR-1 in different histological subtypes of benign and in anaplastic meningiomas.

Materials and methods. 32 cases of meningiomas which were removed during neurosurgical operations were analyzed. We studied peculiarities of the expression of angiogenesis markers in benign and malignant brain meningiomas.

Results. VEGF expression was observed in tumor cells as well as in endothelial cells in 38, 8% of all cases. Tumors with weak, focal expression and also with immunonegative areas comprised 22, 2% of investigated cases. Expression of VEGFR-1 in microvessel endothelial cells was present in 61, 1% of analysed cases.

Conclusions.: 1. The expression level of VEGF significantly differs among various subtypes of benign meningiomas with the most intensive expression in transitional subtypes.

2. Fibroblastic subtypes of benign meningiomas are characterized by the least expression level of VEGF and VEGFR-1.

3. The relationship between the grade of meningiomas according to the WHO classification (2007) and the expression level of VEGF was not determined. Thus, the angiogenic potential depends upon the histological structure and does not depend on the degree of malignancy.

4. The expression level of VEGFR-1 doesn’t significantly differ between benign and anaplastic meningiomas.


Sherwood L, Parris E, Folkman J. Tumor Angiogenesis: Therapeutic Implications. New England Journal of Medicine. 1971;285(21):1182-1186. CrossRef

Fang S, Salven P. Stem cells in tumor angiogenesis. Journal of Molecular and Cellular Cardiology. 2011;50(2):290-295. CrossRef

Pradeep C. Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies. Integrative Cancer Therapies. 2005;4(4):315-321. CrossRef

Schenone S, Bondavalli F, Botta M. Antiangiogenic Agents: an Update on Small Molecule VEGFR Inhibitors. Current Medicinal Chemistry. 2007;14(23):2495-2516. CrossRef

Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. Dan Med J. 2013;60(4):4626. PubMed

Erovic B, Neuchrist C, Berger U, El-Rabadi K, Burian M. Quantitation of microvessel density in squamous cell carcinoma of the head and neck by computer-aided image analysis. Wiener klinische Wochenschrift. 2005;117(1-2):53-57. CrossRef

Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathology. 2011;28(2):99-106. CrossRef

Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-676. CrossRef

Barresi V, Tuccari G. Increased ratio of vascular endothelial growth factor to semaphorin3A is a negative prognostic factor in human meningiomas. Neuropathology. 2010. CrossRef

Preusser M, Hassler M, Birner P et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. NP. 2012;31(09):352-360. CrossRef

Verma S, Dharmalingam P, Roopesh Kumar V. Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma. Indian J Pathol Microbiol. 2013;56(4):349. CrossRef

Pfister C, Pfrommer H, Tatagiba M, Roser F. Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro. British Journal of Cancer. 2012;107(10):1702-1713. CrossRef

Baumgarten P1, Brokinkel B, Zinke J, Zachskorn C, Ebel H, Albert FK, Stummer W, Plate KH, Harter PN, Hasselblatt M, Mittelbronn M. Expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR1 and VEGFR2 in primary and recurrent WHO grade III meningiomas. Histol. Histopathol. 2013;28(9):1157-1166. PubMed

Lamszus K, Lengler U, Schmidt N, Stavrou D, Ergün S, Westphal M. Vascular Endothelial Growth Factor, Hepatocyte Growth Factor/Scatter Factor, Basic Fibroblast Growth Factor, and Placenta Growth Factor in Human Meningiomas and Their Relation to Angiogenesis and Malignancy. Neurosurgery. 2000;46(4):938-948. CrossRef

Otsuka S, Tamiya T, Ono Y et al. The relationship between peritumoral brain edema and the expression of vascular endothelial growth factor and its receptors in intracranial meningiomas. Journal of Neuro-Oncology. 2004;70(3):349-357. CrossRef

Louis D, Ohgaki H, Wiestler O, Cavenee W. World Health Organization Classification of Tumours of the Central Nervous System. Louis D, editor. Lyon:IARC; 2007.

Raica M, Cimpean A, Anghel A. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma. Neoplasma. 2007;54:278-284.

Ferreira T, Rasband WS. ImageJ User Guide. IJ 1.46r [Internet]. 2010—2012. Available at:



How to Cite

Voteva, W. (2014). Pathomorphological and immunohistochemical characteristics of vascularisation in benign and malignant meningiomas of the brain. Ukrainian Neurosurgical Journal, (4), 65–70.



Original articles